$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

$uncy Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024027202 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$675.0K
YoY Change			-29.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.391M	$2.080M	$8.547M
YoY Change	3756.45%	40.07%	2131.59%
% of Gross Profit
Research & Development	$6.813M	$4.233M	$12.90M
YoY Change	124.85%	10.23%	3.75%
% of Gross Profit
Depreciation & Amortization	$9.000K	-$1.000K	$9.000K
YoY Change	350.0%	-150.0%	-97.9%
% of Gross Profit
Operating Expenses	$9.204M	$6.313M	$21.45M
YoY Change	88.72%	18.55%	12.87%
Operating Profit	-$9.204M		-$20.77M
YoY Change	119.04%		15.08%
Interest Expense	$20.00K	$121.0K	$82.00K
YoY Change	66.67%	-4133.33%	1266.67%
% of Operating Profit
Other Income/Expense, Net	-$11.76M	-$1.606M	-$9.770M
YoY Change	13.34%		162733.33%
Pretax Income	-$20.96M	-$7.798M	-$30.54M
YoY Change	43.83%	46.36%	69.14%
Income Tax
% Of Pretax Income
Net Earnings	-$20.96M	-$7.798M	-$30.54M
YoY Change	43.83%	46.36%	69.14%
Net Earnings / Revenue			-4525.04%
Basic Earnings Per Share	-$0.61		-$1.28
Diluted Earnings Per Share	-$0.61	-$0.22	-$1.28
COMMON SHARES
Basic Shares Outstanding	34.76M shares	34.75M shares	24.54M shares
Diluted Shares Outstanding	34.91M shares		24.54M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.93M	$9.701M	$9.701M
YoY Change	101.09%	2032.09%	2032.09%
Cash & Equivalents	$48.93M	$9.701M
Short-Term Investments
Other Short-Term Assets	$2.746M	$3.698M	$3.698M
YoY Change	48.27%	68.94%	68.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.68M	$13.40M	$13.40M
YoY Change	97.36%	406.77%	406.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.00K	$26.00K	$792.0K
YoY Change	9.52%	18.18%	355.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$709.0K	$792.0K	$792.0K
YoY Change	-30.35%	355.17%	355.17%
TOTAL ASSETS
Total Short-Term Assets	$51.68M	$13.40M	$13.40M
Total Long-Term Assets	$709.0K	$792.0K	$792.0K
Total Assets	$52.39M	$14.19M	$14.19M
YoY Change	92.58%	403.58%	403.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.240M	$839.0K	$839.0K
YoY Change	56.96%	-5.94%	-5.94%
Accrued Expenses	$3.550M	$3.234M	$3.561M
YoY Change	109.07%	44.57%	48.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.28M	$17.53M	$17.53M
YoY Change	89.62%	433.92%	433.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$372.0K	$466.0K	$466.0K
YoY Change	-47.97%
Total Long-Term Liabilities	$372.0K	$466.0K	$466.0K
YoY Change	-47.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.28M	$17.53M	$17.53M
Total Long-Term Liabilities	$372.0K	$466.0K	$466.0K
Total Liabilities	$30.65M	$18.00M	$18.00M
YoY Change	83.72%	448.11%	448.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.50M	-$64.50M
YoY Change	76.03%	89.72%
Common Stock	$37.00K	$35.00K
YoY Change	146.67%	133.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$24.46M	-$3.809M	-$3.809M
YoY Change
Total Liabilities & Shareholders Equity	$52.39M	$14.19M	$14.19M
YoY Change	92.58%	403.58%	403.58%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$20.96M	-$7.798M	-$30.54M
YoY Change	43.83%	46.36%	69.14%
Depreciation, Depletion And Amortization	$9.000K	-$1.000K	$9.000K
YoY Change	350.0%	-150.0%	-97.9%
Cash From Operating Activities	-$6.456M	-$4.443M	-$18.28M
YoY Change	64.69%	-26.97%	16.82%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$2.000K	$12.00K
YoY Change			500.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.000K	-$2.000K	-$12.00K
YoY Change			500.0%
FINANCING ACTIVITIES
Cash Dividend Paid			$900.0K
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$45.69M	-209.0K	$27.54M
YoY Change	64.37%	-55.63%	-5947.35%
NET CHANGE
Cash From Operating Activities	-$6.456M	-4.443M	-$18.28M
Cash From Investing Activities	-$6.000K	-2.000K	-$12.00K
Cash From Financing Activities	$45.69M	-209.0K	$27.54M
Net Change In Cash	$39.23M	-4.654M	$9.246M
YoY Change	64.3%	-29.0%	-157.34%
FREE CASH FLOW
Cash From Operating Activities	-$6.456M	-$4.443M	-$18.28M
Capital Expenditures	$6.000K	$2.000K	$12.00K
Free Cash Flow	-$6.462M	-$4.445M	-$18.30M
YoY Change	64.85%	-26.94%	16.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15057049	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24539309	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15057049	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24539309	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40582
CY2023	dei	Entity Registrant Name EntityRegistrantName	UNICYCIVE THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3638692
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4300 El Camino Real
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Altos
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94022
CY2023	dei	City Area Code CityAreaCode	(650)
CY2023	dei	Local Phone Number LocalPhoneNumber	351-4495
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	UNCY
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	19502100	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34756436	shares
CY2023	dei	Auditor Firm AuditorFirmId	606
CY2023	dei	Auditor Name AuditorName	Grassi & Co., CPAs, P.C
CY2023	dei	Auditor Location AuditorLocation	Jericho, New York
CY2022Q4	us-gaap	Cash Cash	455000	usd
CY2023Q4	us-gaap	Cash Cash	9701000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2189000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3698000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2644000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	13399000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	152000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	766000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000	usd
CY2022Q4	us-gaap	Assets Assets	2818000	usd
CY2023Q4	us-gaap	Assets Assets	14191000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	892000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	839000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2237000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13134000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	327000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3284000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17534000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	466000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3284000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	18000000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9926161	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15231655	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15231655	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34756049	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34756049	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33516000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60697000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33997000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64541000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3809000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2818000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14191000	usd
CY2022	us-gaap	Revenues Revenues	951000	usd
CY2023	us-gaap	Revenues Revenues	675000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12436000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12902000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6567000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8547000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	19003000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	21449000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18052000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-20774000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	615000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6000	usd
CY2023	us-gaap	Interest Expense InterestExpense	82000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10303000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9770000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-30544000	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	867000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18058000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31411000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15057049	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24539309	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	21000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1047000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-466000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-30544000	usd
CY2023	uncy	Stock Issued During Period Value Deemed Dividends On Series A1 Preferred Stock StockIssuedDuringPeriodValueDeemedDividendsOnSeriesA1PreferredStock	867000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	26274000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1767000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3809000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-30544000	usd
CY2022	us-gaap	Depreciation Depreciation	7000	usd
CY2023	us-gaap	Depreciation Depreciation	9000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	21000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1047000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1767000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	154000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	275000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10303000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1117000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1267000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1276000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-151000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-252000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15651000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18283000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	482000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	496000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	30190000	usd
CY2023	uncy	Issuance Costs Related To Issuance Of Series A1 Preferred Stock And Warrants IssuanceCostsRelatedToIssuanceOfSeriesA1PreferredStockAndWarrants	-2153000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-471000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27541000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16124000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9246000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16579000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	455000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	455000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9701000	usd
CY2022	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	420000	usd
CY2023	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	349000	usd
CY2022	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	240000	usd
CY2023	uncy	Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets DeferredInsuranceChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	270000	usd
CY2023	uncy	Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr	26274000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	867000	usd
CY2023	uncy	Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock	2831000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	24000	usd
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2016-08-18
CY2023	uncy	Licensing Revenue LicensingRevenue	700000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include stock-based compensation and valuation of warrant liabilities. Actual results may materially differ from those estimates.</p>
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13134000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	13134000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10300000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. All of the Company’s cash was deposited in one account at a financial institution during 2022. Beginning in 2023, the Company’s cash and cash equivalents are distributed across multiple financial institutions. Cash balances may at times exceed federally insured limits. Cash and cash equivalents could be adversely impacted, including the loss of uninsured deposits and other uninsured financial assets, if one or more of the financial institutions in which the Company holds its cash or cash equivalents fails or is subject to other adverse conditions in the financial or credit markets. No such losses have been incurred through December 31, 2023.</p>
CY2023	uncy	Payment Of Vender Net Revenue PaymentOfVenderNetRevenue	2000000	usd
CY2023	uncy	Vendor Payment VendorPayment	2000000	usd
CY2023	uncy	Consecutive Year ConsecutiveYear	P4Y
CY2023	uncy	Total Payments Of Commercial Supplies TotalPaymentsOfCommercialSupplies	10000000	usd
CY2017Q4	uncy	Agreement Due Payments AgreementDuePayments	50000	usd
CY2017Q4	uncy	Second Clinical Trial Payment SecondClinicalTrialPayment	50000	usd
CY2017Q4	uncy	Royalty Pecentage RoyaltyPecentage	0.02	pure
CY2021Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	50000000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2200000	usd
CY2023	uncy	Sublicense Income Percentage SublicenseIncomePercentage	0.40	pure
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	200000	usd
CY2022Q1	uncy	Revisions Reduced The Overall Budget RevisionsReducedTheOverallBudget	3300000	usd
CY2023	uncy	Total Related Payments TotalRelatedPayments	2500000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	600000	usd
CY2022Q3	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	100000	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1300000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	400000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	300000	usd
CY2023Q1	uncy	Milestone Payments MilestonePayments	3700000	usd
CY2023	us-gaap	Capital Leases Indemnification Agreements Payments CapitalLeasesIndemnificationAgreementsPayments	3700000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000	usd
CY2023	us-gaap	Debt And Equity Securities And Foreign Currency Transaction Price Change Unrealized Gain Loss Operating Before Tax DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax	675000000	usd
CY2023	uncy	Transaction Price TransactionPrice	675000000	usd
CY2023Q4	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	700	usd
CY2023Q4	uncy	Credit Card Liability CreditCardLiability	18000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	892000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	839000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	476000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	270000	usd
CY2022Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	1554000	usd
CY2023Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	3103000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	159000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	325000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2189000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3698000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	846000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	821000	usd
CY2022Q4	uncy	Credit Card Liability CreditCardLiability	46000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1487000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1917000	usd
CY2022Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	228000	usd
CY2023Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	1034000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	522000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	283000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2237000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	usd
CY2021Q4	us-gaap	Area Of Land AreaOfLand	2367	sqft
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2023Q1	us-gaap	Area Of Land AreaOfLand	2456	sqft
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	three additional years
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1000000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10	pure
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	331000000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	173000000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	354000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	391000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	424000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	72000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	887000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	94000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	793000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	327000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	466000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	210000000	usd
CY2023	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	6000000	usd
CY2023	us-gaap	Related Party Transaction Terms And Manner Of Settlement RelatedPartyTransactionTermsAndMannerOfSettlement	June 30, 2022
CY2021Q4	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	60000000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	107000000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Share Price SharePrice	5
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	736773	shares
CY2023	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	184193	shares
CY2022Q4	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding	4784193	shares
CY2022Q4	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceOutstanding	6
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y6M14D
CY2023Q4	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsOutstanding	4784193	shares
CY2023Q4	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceOutstanding	6
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y6M14D
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	(i) shares of common stock of the Company and, if applicable, shares of Series A-2 Preferred Stock, in lieu of common stock, (ii) a tranche A warrant to acquire approximately 46,675,940 shares (excluding deemed dividends) of Series A-3 Preferred Stock (the “Tranche A Warrant”), (iii) a tranche B warrant to acquire approximately 42,432,672 shares (excluding deemed dividends) of Series A-4 Preferred Stock (the “Tranche B Warrant”), and (iv) a tranche C warrant to acquire approximately 67,892,276 shares (excluding deemed dividends) of Series A-5 Preferred Stock (the “Tranche C Warrant”, together with the Tranche A Warrant and the Tranche B Warrant, the “Warrants”). The Tranche A Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company’s announcement of receipt of FDA approval for Oxylanthanum Carbonate, the Tranche B Warrant, for an aggregate exercise price of approximately $25 million, is exercisable until 21 days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment (“TDAPA”) approval for Oxylanthanum Carbonate, and the Tranche C Warrant for an aggregate exercise price of approximately $50 million is exercisable until 21 days following four quarters of commercial sales of Oxylanthanum Carbonate following receipt of TDAPA approval.
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2800000	usd
CY2023Q4	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	25400000	usd
CY2023Q3	us-gaap	Shares Issued SharesIssued	19516205	shares
CY2023Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	43649	shares
CY2023	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.14	pure
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	900000	usd
CY2023Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	28.71
CY2023	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	(A) the liquidation preference with respect to such share of Series A-1 Preferred Stock, divided by (B) the conversion price, provided that, to the extent the share conversion would cause such Holder’s beneficial ownership to exceed 9.99%, such holder shall receive shares of Series A-2 Preferred Stock in lieu of common stock, on a one-for-one basis, with respect to the number of shares of common stock that exceed 9.99% ownership, (2) a Tranche A Warrant, (3) a Tranche B Warrant, and (4) a Tranche C Warrant.
CY2023	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	1000
CY2023	us-gaap	Extended Product Warranty Description ExtendedProductWarrantyDescription	the fair value of the Warrants was determined using a Black Scholes model using parameters including (i) the exercise price of the warrant, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate, and (vi) estimated probability assumptions surrounding the achievement by the Company of technical milestones associated with regulatory and commercial progress.
CY2023Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	2800000	usd
CY2023	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	13100000	usd
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1302326	shares
CY2023	us-gaap	Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance	12775996	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	389676	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2815503	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1342670	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.75
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M19D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	52000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8989487	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.75
CY2023	uncy	Share Based Compensation Arrangementby Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y7M9D
CY2023	uncy	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	1072000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	21882	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.39
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8189	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.27
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10302086	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1196000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	915187	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M9D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	96000	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5700000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	5000000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2Y10M24D
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	10000	shares
CY2023Q3	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	7500000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.75
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4000000	usd
CY2021	uncy	Exercised Stock Option ExercisedStockOption	383721	shares
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	119000000	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1357	shares
CY2023	uncy	Unvested Options Amount UnvestedOptionsAmount	4000000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	27000000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	382364	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	10000	shares
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	7200000	usd
CY2022Q2	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	0.72
CY2023	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	1000000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	26738	shares
CY2021Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	100000000	usd
CY2021Q3	us-gaap	Option Contract Indexed To Equity Settlement Share Fair Value Per Share OptionContractIndexedToEquitySettlementShareFairValuePerShare	3.74
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1047000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1767000	usd
CY2023	uncy	Annual Net Cash Flow From Operations Percentage AnnualNetCashFlowFromOperationsPercentage	0.75	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0239	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0048	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2404	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1224	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0708	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0065	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0216	pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	373000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	427000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4156000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5976000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	428000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	389000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2221000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4106000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	292000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	439000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7470000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11337000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7438000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	32000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	161000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	32000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	161000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	161000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	24700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	11600000	usd
CY2023Q4	uncy	Taxable Income Percentage TaxableIncomePercentage	0.80	pure
CY2023Q4	uncy	Income Tax Expense Benefit Percentage IncomeTaxExpenseBenefitPercentage	0.50	pure
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	101000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	690000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	589000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	152000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	184000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	690000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1027000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-30544000	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	867000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18058000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31411000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15057049	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24539309	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6126863	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	176044446	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants		usd
CY2022	uncy	Issuance Costs Related To Issuance Of Series A1 Preferred Stock And Warrants IssuanceCostsRelatedToIssuanceOfSeriesA1PreferredStockAndWarrants		usd
CY2022	uncy	Issuance Of Series A2 Preferred Stock And Common Stock Upon Conversion Of Series A1 Preferr IssuanceOfSeriesA2PreferredStockAndCommonStockUponConversionOfSeriesA1Preferr		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	uncy	Fair Value Of Warrants Issued In Connection With The Issuance Of Preferred Stock FairValueOfWarrantsIssuedInConnectionWithTheIssuanceOfPreferredStock		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsGranted
CY2023	uncy	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsGranted		usd
CY2023	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Shares Underlying Outstanding Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesUnderlyingOutstandingWarrantsExercised		shares
CY2023	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceWarrantsExercised
CY2023	uncy	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Termin Years Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTerminYearsWarrantsExercised
CY2023	uncy	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Warrants Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueWarrantsExercised		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18058000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31411000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001766140

Files In Submission

Name	View Source	Status
0001213900-24-027202-index-headers.html	Edgar Link	pending
0001213900-24-027202-index.html	Edgar Link	pending
0001213900-24-027202.txt	Edgar Link	pending
0001213900-24-027202-xbrl.zip	Edgar Link	pending
ea0202007-10k_unicy.htm	Edgar Link	pending
ea0202007ex23-1_unicy.htm	Edgar Link	pending
ea0202007ex23-2_unicy.htm	Edgar Link	pending
ea0202007ex31-1_unicy.htm	Edgar Link	pending
ea0202007ex31-2_unicy.htm	Edgar Link	pending
ea0202007ex32-1_unicy.htm	Edgar Link	pending
ea0202007ex32-2_unicy.htm	Edgar Link	pending
ea0202007ex97-1_unicy.htm	Edgar Link	pending
ex23-2_001.jpg	Edgar Link	pending
ex23-2_002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
ea0202007-10k_unicy_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uncy-20231231.xsd	Edgar Link	pending
uncy-20231231_def.xml	Edgar Link	unprocessable
uncy-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
uncy-20231231_cal.xml	Edgar Link	unprocessable
uncy-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

2024 Q1 Form 10-K Financial Statement

#000121390024027202 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY Unicycive Therapeutics, Inc. Stock $uncy

2024 Q1 Form 10-K Financial Statement

#000121390024027202 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy